Many congratulations to Craig Burd, whose R01 entitled "Estrogen receptor beta is a targetable melanoma tumor suppressor" was recently funded for five years! Building on observations that melanoma is more common in men than in women, and that decreased levels of estrogen receptor beta (ERβ) are correlated with disease progression, Dr. Burd and his team propose that signaling through ERβ regulates melanocyte biology, impacts immune recognition of the melanoma tumors, and that estrogen signaling protects against melanoma.  These studies will also As an integral part of  evaluate the potential of ERβ-specific agonists in enhancing current melanoma therapies.

Congratulations to Dr. Burd and his lab!